Latest News on MLYS

Financial News Based On Company


Advertisement
Advertisement

Is Mineralys Therapeutics (MLYS) Cheap As Transform HTN Data Strengthens Its FDA Case?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/is-mineralys-therapeutics-mlys-cheap-as-transform-htn-data-s
Mineralys Therapeutics (MLYS) recently released positive long-term Transform-HTN extension data for lorundrostat, showing sustained blood pressure reductions and a favorable safety profile, which could strengthen its FDA case. Despite the positive data, the stock has seen significant declines over the past 30 days and year-to-date, trading at a steep discount to analyst targets and intrinsic value estimates. While analysts see it as 66% undervalued, a P/B ratio comparison to peers suggests it might carry a premium based on balance sheet value.

Form 144 Mineralys Therapeutics For: 15 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-15-november-93CH-2808700
This article from Investing.com announces the filing of Form 144 for Mineralys Therapeutics, specifically referencing activity on November 15. The publication time is listed as November 16, 2026, at 00:02. The content appears to be a brief news update rather than an in-depth report.

Mineralys Therapeutics stock hits 52-week low at 14.89 USD By Investing.com

https://ca.investing.com/news/stock-market-news/mineralys-therapeutics-stock-hits-52week-low-at-1489-usd-93CH-4957247
Mineralys Therapeutics Inc. stock has hit a 52-week low of $14.89, trading just above this mark at $14.97, representing a 65% decline over the past year. Despite the drop, InvestingPro analysis suggests the stock is undervalued. The company also reported a wider Q3 loss but maintains sufficient cash reserves through 2028 as it awaits an FDA decision on its experimental hypertension drug, lorundrostat, in December.

Mineralys Therapeutics stock hits 52-week low at 14.89 USD

https://www.investing.com/news/company-news/mineralys-therapeutics-stock-hits-52week-low-at-1489-usd-93CH-5025921
Mineralys Therapeutics (MLYS) stock has fallen to a new 52-week low of $14.89, representing a 65% decline over the past year. Despite its current struggles and a wider third-quarter loss of $57.3 million, InvestingPro analysis suggests the stock is undervalued, and the company maintains $624.7 million in cash reserves, awaiting an FDA decision on its hypertension drug lorundrostat in December.

Mineralys Therapeutics, Inc. (MLYS) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/MLYS/
This article provides a detailed financial overview of Mineralys Therapeutics, Inc. (MLYS), including its current stock price, historical performance, and key financial statistics. It highlights the company's focus on developing treatments for cardiorenal conditions and includes analyst ratings and earnings trends.
Advertisement

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

https://www.quantisnow.com/insight/mineralys-therapeutics-presents-new-late-breaking-data-from-transform-htn-open-label-extension-6779802
Mineralys Therapeutics has presented new late-breaking data from its Transform-HTN open-label extension trial of lorundrostat, showing a sustained reduction in systolic blood pressure of 17.8 mmHg at Week 48. The drug was reported to be well tolerated, with an FDA PDUFA target date set for December 22, 2026. While the results are positive for shareholders, the open-label nature of the study means there was no placebo comparison, and some participants discontinued due to adverse events, including hyperkalemia.

Mineralys Therapeutics reports long-term lorundrostat data

https://mugglehead.com/mineralys-therapeutics-lorundrostat-transform-htn-long-term-results/
Mineralys Therapeutics announced positive long-term data for its hypertension treatment, lorundrostat, showing a 17.8 mmHg reduction in blood pressure from baseline after 48 weeks. The FDA is expected to make a decision on lorundrostat's approval by December 22. The company also reported strong liquidity, with $624.7 million in cash and investments as of September 30, supporting operations and potential commercialization into 2028.

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

https://quantisnow.com/insight/mineralys-therapeutics-presents-new-late-breaking-data-from-transform-htn-open-label-extension-6779802
Mineralys Therapeutics announced positive long-term results from its Transform-HTN open-label extension trial of lorundrostat, showing a sustained reduction in systolic blood pressure of 17.8 mmHg at Week 48. The drug was well tolerated, with 56% of participants achieving blood pressure below 130 mmHg. The FDA review for lorundrostat is ongoing, with a PDUFA target date of December 22, 2026.

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

https://www.globenewswire.com/news-release/2026/11/08/3398023/0/en/mineralys-therapeutics-presents-new-late-breaking-data-from-transform-htn-open-label-extension-trial-of-lorundrostat-in-hypertension-at-aha-scientific-sessions-2026.html
Mineralys Therapeutics announced positive long-term results from its Transform-HTN open-label extension trial of lorundrostat, showing sustained reductions in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48. Over half of participants achieved the target AOSBP below 130 mmHg, and the treatment was well tolerated with no new safety concerns. The U.S. FDA is currently reviewing lorundrostat, with a PDUFA target date of December 22, 2026.

Mineralys Therapeutics, Inc. (MLYS) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/MLYS/seasonality/
The article provides a seasonal returns chart for Mineralys Therapeutics, Inc. (MLYS), showcasing the average monthly price return from 2023 to 2026. It indicates the stock's current real-time price on NasdaqGS and its performance at market close and after hours on November 6. The content also includes general market data for Canada and other regions.
Advertisement

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/06/3397488/0/en/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
Mineralys Therapeutics, Inc. announced that its Compensation Committee granted inducement stock option and restricted stock unit awards to a new non-executive employee on November 3, 2026. These awards, covering 14,880 shares and 11,160 shares respectively, were issued under the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period, in accordance with Nasdaq Listing Rule 5635(c)(4).

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

https://sg.finance.yahoo.com/news/mineralys-therapeutics-reports-inducement-awards-130000347.html
Mineralys Therapeutics, Inc. announced inducement stock option and restricted stock unit awards to a new non-executive employee on November 3, 2026. These awards, covering 14,880 shares and 11,160 shares respectively, were granted under the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period. The grants comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employee's new employment.

Mineralys Therapeutics, Inc. (MLYS) Tops Q3 EPS by 11c

https://www.streetinsider.com/Earnings/Mineralys+Therapeutics%2C+Inc.+%28MLYS%29+Tops+Q3+EPS+by+11c/27293834.html
Mineralys Therapeutics, Inc. (MLYS) announced its Q3 earnings, reporting an EPS of ($0.64). This figure was $0.11 better than the analyst consensus estimate of ($0.75). The company's stock price currently stands at $17.00.

Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...

https://sg.finance.yahoo.com/news/mineralys-therapeutics-inc-mlys-q3-071348073.html
Mineralys Therapeutics Inc. reported strong Phase 3 data for lorundrostat in its Q3 2026 earnings call, showing robust efficacy in blood pressure reduction and a favorable safety profile. The company is well into commercial launch preparations, backed by a strong cash position expected to fund operations into 2028. Despite an increased net loss due to higher commercialization expenses, Mineralys aims to address the significant market for uncontrolled/resistant hypertension, evaluating future indications beyond hypertension.

Mineralys Therapeutics Q3FY27 Results: Net loss widens to $57.3 million

https://scanx.trade/stock-market-news/companies/mineralys-therapeutics-q3fy27-results-net-loss-widens-57-3-million/55385536
Mineralys Therapeutics reported a significant widening of its net loss to $57.3 million in Q3 2026, primarily due to increased commercialization expenses for its lead candidate, Lorundrostat. The company's cash reserves stand at $624.7 million, projected to fund operations until 2028. This period marks a strategic shift from R&D to market entry, with preparations underway for a potential FDA approval by December 22, 2026.
Advertisement

Mineralys Therapeutics Announces Derek DiRocco's Board Resignation Effective December 31 and Q3 2026 Financial Results

https://kalkinemedia.com/us/news/announcements/mineralys-therapeutics-announces-derek-diroccos-board-resignation-effective-december-31-and-q3-2026-financial-results
Mineralys Therapeutics, Inc. announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026. The company stated that his departure was not due to any disagreements. Additionally, Mineralys Therapeutics disclosed its financial performance for the quarter ending September 30, 2026, identifying itself as an emerging growth company with its common stock traded on NASDAQ under the ticker MLYS.

What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:51e6470cc094b:0-what-mineralys-therapeutics-mlys-said-on-its-q3-earnings-call/
Mineralys Therapeutics (MLYS) discussed its Q3 earnings, focusing on the upcoming FDA decision for its hypertension drug candidate, lorundrostat, targeted for December 22. The company detailed its commercialization preparations, including sales team deployment and payer engagement, anticipating initial commercial insurance coverage. Mineralys also provided clinical updates from its LAUNCH-HTN and EXPLORE-OSA trials, highlighting lorundrostat's efficacy in reducing blood pressure and announcing further long-term data presentations.

A $200M license payment factors into Mineralys (MLYS)'s widening nine-month loss.

https://www.stocktitan.net/sec-filings/MLYS/10-q-mineralys-therapeutics-inc-quarterly-earnings-report-61099a2f553d.html
Mineralys Therapeutics (MLYS) reported a significant increase in its net loss, reaching $337.7 million for the nine months ended September 30, 2026, compared to $122.4 million a year earlier. This widening loss is largely attributed to a $200.0 million upfront payment made to Tanabe under amended license terms for lorundrostat, which also eliminated future royalties and transferred intellectual property rights to Mineralys. Despite the loss, the company believes its $624.7 million in cash, cash equivalents, and investments are sufficient to fund operations for at least 12 months, including the commercial launch of lorundrostat, for which the FDA has set a PDUFA target date of December 22, 2026.

Mineralys Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62897821/mineralys-therapeutics-q3-2026-earnings-call-transcript
Mineralys Therapeutics held its Q3 2026 earnings call, detailing preparations for potential FDA approval of Lorundrostat, targeting the unmet need in uncontrolled and resistant hypertension with a PDUFA date of December 22, 2026. The company reported strong cash reserves of $624.7 million, sufficient to fund operations into 2028, and highlighted promising clinical trial data from Phase 3 Launch HTN and Phase 2 EXPLORE OSA trials. Mineralys is also advancing commercialization efforts, including establishing a sales team, engaging payers, and developing patient support programs, while monitoring competitive dynamics and evaluating future indications for Lorundrostat.

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.globenewswire.com/news-release/2026/11/04/3395833/0/en/mineralys-therapeutics-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
Mineralys Therapeutics announced its third-quarter 2026 financial results, highlighting ongoing preparations for the commercial launch of lorundrostat, an investigational treatment for hypertension, with a PDUFA target date of December 22, 2026. New analyses from the Launch-HTN trial showed lorundrostat significantly reduced systolic blood pressure and albuminuria, while an upcoming presentation at AHA Scientific Sessions will feature long-term data from the Transform-HTN trial. The company reported $624.7 million in cash, cash equivalents, and investments as of September 30, 2026, sufficient to fund operations into 2028.
Advertisement

Did Kidney Trial Results Just Shift Mineralys Therapeutics Stock Investment Narrative?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/did-kidney-trial-results-just-shift-mineralys-therapeutics-s
Mineralys Therapeutics announced the publication of full Phase 2 Explore-CKD data for lorundrostat, showing statistically significant reductions in systolic blood pressure and urinary albumin-to-creatinine ratio in patients with uncontrolled hypertension, CKD, and albuminuria. This data strengthens the clinical evidence for lorundrostat and could impact future label expansion, pricing, and commercial value. The company's investment narrative now focuses on advancing lorundrostat to an approved product, with analysts projecting significant revenue and a shift to profitability by 2029.

How InvestingPro’s Fair Value flagged Mineralys stock before 50% drop By Investing.com

https://www.investing.com/news/investment-ideas/how-investingpros-fair-value-flagged-mineralys-stock-before-50-drop-93CH-4998294
InvestingPro's Fair Value analysis accurately predicted a significant drop in Mineralys Therapeutics (NASDAQ: MLYS) stock, flagging it as overvalued in September 2025 when shares were trading at $33.14. Despite a 144% surge, the analysis calculated its fair value at $17.26, warning of substantial downside risk. Shares subsequently plummeted over 50% to $16 by November 2026, validating the initial assessment and highlighting the tool's ability to help investors avoid costly mistakes.

Three fireside chats will feature Mineralys managers, starting Nov. 10.

https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-participate-in-upcoming-investor-oc0mgehmx2h3.html
Mineralys Therapeutics (Nasdaq: MLYS) announced that its senior management will participate in fireside chats at three upcoming healthcare investor conferences: Guggenheim on November 10, 2026; Stifel on November 12, 2026; and the 9th Annual Evercore Healthcare Conference on December 1, 2026. The biopharmaceutical company focuses on developing medicines for hypertension and aldosterone-related conditions. Live webcasts and archives of these sessions will be available on the company's Investor Relations website.

Mineralys Therapeutics to present at three upcoming investor conferences in November and December 2026

https://pluang.com/en/news-feed/mineralys-therapeutics-konferensi-investor-november-2026
Mineralys Therapeutics announced that its senior management will participate in three investor conferences in November and December 2026, including the Guggenheim Healthcare Innovation Conference, the Stifel Healthcare Conference, and the Evercore Healthcare Conference. The company will provide updates on its progress, particularly regarding its lead drug candidate, lorundrostat, which targets aldosterone-related diseases. Live webcasts and archives of the presentations will be available on Mineralys' website for investors.

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/03/3394793/0/en/mineralys-therapeutics-to-participate-in-upcoming-investor-conferences.html
Mineralys Therapeutics, Inc. announced that its senior management will participate in fireside chats at three upcoming investor conferences: the Guggenheim Healthcare Innovation Conference on November 10, 2026, the Stifel Healthcare Conference on November 12, 2026, and the 9th Annual Evercore Healthcare Conference on December 1, 2026. The company, focused on developing treatments for hypertension and aldosterone-related conditions, will provide webcasts and archives of these chats on its investor relations website.
Advertisement

Mineralys Sets November 4 Earnings Call as Drug Trials Advance

https://www.mychesco.com/a/news/regional/mineralys-sets-november-4-earnings-call-as-drug-trials-advance/
Mineralys Therapeutics Inc. (Nasdaq: MLYS) will report its third-quarter 2026 financial results on November 4 after U.S. markets close, with a conference call and webcast scheduled for 4:30 p.m. Eastern Time. The announcement will provide an update on the company's experimental hypertension treatment, lorundrostat, an oral aldosterone synthase inhibitor. Mineralys focuses its research on uncontrolled and resistant hypertension and related conditions.

Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial

https://www.mychesco.com/a/news/regional/mineralys-drug-lowers-blood-pressure-in-kidney-disease-trial/
Mineralys Therapeutics Inc. reported that its experimental drug, lorundrostat, significantly reduced blood pressure and urinary protein levels in patients with chronic kidney disease during a Phase 2 clinical trial. The study, published in Kidney International, found a statistically significant reduction in systolic blood pressure and albuminuria, supporting the drug's potential beyond uncontrolled hypertension. While promising, the findings from the short-term trial do not yet establish long-term kidney function benefits, and further evaluation is planned.

Mineralys Therapeutics, Inc. (MLYS) Seasonal returns chart

https://uk.finance.yahoo.com/quote/MLYS/seasonality/
This article provides a seasonal returns chart for Mineralys Therapeutics, Inc. (MLYS), showing average monthly price returns from 2023 to 2026. It also includes current stock performance data, detailing its price at market close and after hours, and announces an upcoming Q3 2026 earnings call.

Mineralys Heads Into Final Pre-PDUFA Report With Launch Readiness And Cash Burn In Focus

https://finviz.com/news/411089/mineralys-heads-into-final-pre-pdufa-report-with-launch-readiness-and-cash-burn-in-focus
Mineralys Therapeutics is approaching a critical FDA decision on its drug lorundrostat, due December 22, making its upcoming third-quarter report crucial for launch preparation and financial stability. While a large prior-quarter loss was due to a one-time payment, the market will scrutinize current operating expenses and cash burn to ensure a credible, well-funded product launch is on track. Despite management's confident outlook, shares have declined, indicating investor concerns about competitive pressure or financing.

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

https://www.globenewswire.com/news-release/2026/10/28/3390726/0/en/mineralys-therapeutics-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-wednesday-november-4-2026.html
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it will report its third-quarter financial results for the period ending September 30, 2026, after the market closes on Wednesday, November 4, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Mineralys Therapeutics focuses on developing treatments for hypertension and aldosterone-related conditions.
Advertisement

Mineralys Drug Cuts Kidney Damage Marker 52% in Trial

https://www.mychesco.com/a/news/regional/mineralys-drug-cuts-kidney-damage-marker-52-in-trial/
Mineralys Therapeutics Inc. reported that its experimental hypertension drug, lorundrostat, significantly reduced a key marker of kidney damage by 52.2% in patients with chronic kidney disease during its Phase 3 Launch-HTN trial. The drug also showed significant reductions in systolic blood pressure in both CKD and non-CKD patients, with a favorable safety profile. These findings bolster lorundrostat's clinical profile as the company awaits a December 22 decision from U.S. regulators regarding its use for hypertension.

Adding a medicine lowered the top blood pressure reading by 7.5 mmHg vs placebo in a kidney trial

https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-ptmbyqeadkyh.html
Mineralys Therapeutics announced the publication of Phase 2 Explore-CKD trial results for lorundrostat in Kidney International. The trial showed that lorundrostat 25 mg once daily, added to an SGLT2 inhibitor, significantly reduced systolic blood pressure by 7.5 mmHg placebo-adjusted and reduced urinary albumin-to-creatinine ratio by 25.6% placebo-adjusted in participants with uncontrolled hypertension and chronic kidney disease. These findings suggest lorundrostat's potential benefits for this difficult-to-treat population, with longer-term data expected soon.

Mineralys reports positive phase 2 CKD trial results

https://www.investing.com/news/company-news/mineralys-reports-positive-phase-2-ckd-trial-results-93CH-4978527
Mineralys Therapeutics announced positive results from its Phase 2 Explore-CKD trial of lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled hypertension, chronic kidney disease, and albuminuria. The trial met its primary endpoint, showing a significant reduction in systolic blood pressure and urinary albumin-to-creatinine ratio compared to placebo. The company has submitted a new drug application to the FDA for lorundrostat.

Mineralys Therapeutics Announces Publication of Phase 2

https://www.globenewswire.com/news-release/2026/10/28/3390040/0/en/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-trial-results-for-lorundrostat-in-kidney-international.html
Mineralys Therapeutics announced the publication of full results from its Phase 2 Explore-CKD trial for lorundrostat in Kidney International. The trial showed that lorundrostat 25 mg once daily, when added to an SGLT2 inhibitor, significantly reduced systolic blood pressure and albuminuria in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. These findings suggest lorundrostat could be a valuable treatment option for this difficult-to-treat patient population.

Form 4 Mineralys Therapeutics Inc: Brian Taylor Slingsby (Director) For: 22 September

https://in.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-brian-taylor-slingsby-director-for-22-september-93CH-5656625
This article reports on a Form 4 filing for Mineralys Therapeutics Inc., indicating an insider transaction by Brian Taylor Slingsby, a Director, on September 22. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's insiders. The article notes the stock symbol MLYS and its recent performance.
Advertisement

Mineralys Adds Pharma Veterans Ahead of Potential Drug Launch

https://www.mychesco.com/a/news/regional/mineralys-adds-pharma-veterans-ahead-of-potential-drug-launch/
Mineralys Therapeutics Inc. has appointed Kristine Peterson and Lonnel Coats, two experienced pharmaceutical executives, to its board of directors. This move comes as the company prepares for the potential regulatory approval and commercial launch of lorundrostat, its experimental drug for uncontrolled or resistant hypertension. The appointments aim to strengthen Mineralys' commercial expertise for its transition from clinical development to commercial operations.

H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56

https://www.moomoo.com/news/post/1002180776/hc-wainwright-maintains-mineralys-therapeutics-mlysus-with-buy-rating-maintains
H.C. Wainwright has reiterated its Buy rating for Mineralys Therapeutics (MLYS.US) and maintained its target price at $56. This indicates continued confidence from the firm in the company's prospects.

Mineralys Therapeutics, Inc. Estimates – NASDAQ:MLYS

https://www.tradingview.com/symbols/NASDAQ-MLYS/financials-estimates/
This article provides access to financial actuals and analyst estimates for Mineralys Therapeutics, Inc. (NASDAQ: MLYS) through TradingView. Users can explore reported financial data and compare it with average, high, and low estimates across various financial statements and valuation metrics. The platform allows visualization of trends over time for income statements, balance sheets, and cash flow.

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

https://www.manilatimes.net/2026/10/23/tmt-newswire/globenewswire/mineralys-therapeutics-presents-new-lorundrostat-data-in-participants-with-hypertension-and-chronic-kidney-disease-at-asn-kidney-week-2026/2452399
Mineralys Therapeutics presented new clinical data for lorundrostat at ASN Kidney Week 2026, demonstrating significant blood pressure reductions in participants with and without chronic kidney disease (CKD). The data from the Phase 3 Launch-HTN trial also showed a 52% reduction in albuminuria in CKD patients. These findings validate lorundrostat's potential to address both hypertension and kidney damage, with the drug currently under FDA review.

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

https://www.globenewswire.com/news-release/2026/10/22/3386983/0/en/mineralys-therapeutics-presents-new-lorundrostat-data-in-participants-with-hypertension-and-chronic-kidney-disease-at-asn-kidney-week-2026.html
Mineralys Therapeutics presented new clinical data for lorundrostat at ASN Kidney Week 2026, showing significant blood pressure reductions in participants with and without chronic kidney disease (CKD). The data from the Phase 3 Launch-HTN trial indicated that lorundrostat also reduced albuminuria by 52% in CKD patients compared to placebo. This investigational drug is currently under FDA review for hypertension, with a PDUFA target date of December 22, 2026.
Advertisement

Form 4 Mineralys Therapeutics Inc: Lonnel Coats (Director) For: 19 October

https://uk.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-lonnel-coats-director-for-19-october-93CH-4921077
This article reports on a Form 4 filing for Mineralys Therapeutics Inc, detailing an insider transaction by Director Lonnel Coats. The transaction took place on October 19th. The filing indicates a significant event related to a key individual within the company.

Form 4 Mineralys Therapeutics Inc: Kristine Peterson (Director) For: 19 October

https://uk.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-kristine-peterson-director-for-19-october-93CH-4921149
This article reports on a Form 4 filing for Mineralys Therapeutics Inc., detailing insider transaction activity. The filing indicates that Kristine Peterson, a director at the company, made a transaction on October 19th. The article provides the stock symbol MLYS and its current price performance.

Form 4 Mineralys Therapeutics Inc: Kristine Peterson (Director) For: 19 October

https://ca.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-kristine-peterson-director-for-19-october-93CH-4892023
This article reports on a Form 4 filing for Mineralys Therapeutics Inc, indicating a transaction by Director Kristine Peterson on October 19. Form 4 filings are a standard SEC requirement for reporting changes in ownership of company stock by insiders. The article also notes that Mineralys Therapeutics Inc's stock symbol is MLYS, which saw a -1.53% change.

A director receives rights to 12,400 shares at Mineralys (MLYS), plus options covering 16,600 shares.

https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-2c074b5f4043.html
Mineralys Therapeutics director Kristine Peterson received 12,400 restricted stock units (RSUs) and stock options for 16,600 common shares on October 19, 2026. Both awards are subject to a three-year vesting schedule, contingent on her continued service. The options have an exercise price of $20.92 per share, and the RSUs were granted without additional cash consideration.

People on the Move: Kristine Peterson and Lonnel Coats Join Mineralys Therapeutics Board of Directors

https://biobuzz.io/news/people-on-the-move-kristine-peterson-and-lonnel-coats-join-mineralys-therapeutics-board-of-directors/
Mineralys Therapeutics, a biopharmaceutical company, has appointed Kristine Peterson and Lonnel Coats to its Board of Directors. Both bring over three decades of experience in commercial organizations and launching new therapies, particularly in cardiovascular and metabolic disease. Their appointments come as Mineralys prepares for the potential FDA approval and launch of lorundrostat, its lead candidate for uncontrolled or resistant hypertension.
Advertisement

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

https://www.globenewswire.com/news-release/2026/10/19/3383872/0/en/mineralys-therapeutics-expands-its-board-of-directors-with-the-appointments-of-kristine-peterson-and-lonnel-coats.html
Mineralys Therapeutics announced the appointment of Kristine Peterson and Lonnel Coats to its Board of Directors, bringing extensive commercial and product launch experience. These appointments come as the company prepares for the potential approval and commercial launch of lorundrostat, its treatment for uncontrolled or resistant hypertension, with a PDUFA target action date of December 22. Both new board members have significant backgrounds in launching new therapies across various therapeutic areas, including cardiovascular and metabolic diseases.

Selling Mineralys Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

https://www.moomoo.com/news/post/1001521289/selling-mineralys-therapeutics-shares-at-a-lower-price-than-current
Insiders at Mineralys Therapeutics sold shares at an average price of US$15.69, which is significantly lower than the current market price of US$22.84, suggesting they may have missed out on potential gains. Despite these insider sales, the company's stock has performed well, indicating that insider selling alone isn't always a negative signal. Investors should consider a broader analysis of insider activity, including purchases, to get a complete picture.

Mineralys Therapeutics stock hits 52-week low at 20.4 USD

https://www.investing.com/news/company-news/mineralys-therapeutics-stock-hits-52week-low-at-204-usd-93CH-4954641
Mineralys Therapeutics (MLYS) stock has fallen to a 52-week low of $20.40, marking a 57% decrease from its high and a 52.71% decline over the past year. Despite recent losses, analysts maintain a cautiously optimistic outlook, with price targets ranging from $29 to $56. The company recently reported a wider-than-expected Q2 loss due to increased spending on its potential blood pressure drug, lorundrostat, which is awaiting an FDA decision in December 2026.

Mineralys Drug Lowers Blood Pressure but Misses Sleep Apnea Goal

https://www.mychesco.com/a/news/regional/mineralys-drug-lowers-blood-pressure-but-misses-sleep-apnea-goal/
Mineralys Therapeutics Inc. announced new clinical data for its experimental hypertension drug, lorundrostat. The drug effectively lowered blood pressure in patients with uncontrolled hypertension, with 46% achieving target systolic blood pressure in the Phase 3 Launch-HTN trial. However, a separate Phase 2 Explore-OSA trial showed that while lorundrostat reduced blood pressure in obstructive sleep apnea patients, it did not improve the severity of their sleep apnea, missing its primary efficacy endpoint.

Form 144 Mineralys Therapeutics For: 14 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-14-october-93CH-5632130
This article from Investing.com announces a Form 144 filing for Mineralys Therapeutics, specifically for October 14th. The content is brief, primarily serving as an announcement of the filing within the financial news context. It also highlights the stock symbol MLYS and shows a minor decrease in its value.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement